Tag - Josh Hexter

Feature

Oramed hopes to start Phase 3 oral insulin trial next year

By Len Zehr After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss...

August 23, 2016

Feature

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

December 1, 2015

Tag - Josh Hexter

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed sees value creating events through 2016

General

More